ES2944446T3 - Uso de la modulación de H3K9me3 para potenciar la función cognitiva - Google Patents

Uso de la modulación de H3K9me3 para potenciar la función cognitiva Download PDF

Info

Publication number
ES2944446T3
ES2944446T3 ES20172824T ES20172824T ES2944446T3 ES 2944446 T3 ES2944446 T3 ES 2944446T3 ES 20172824 T ES20172824 T ES 20172824T ES 20172824 T ES20172824 T ES 20172824T ES 2944446 T3 ES2944446 T3 ES 2944446T3
Authority
ES
Spain
Prior art keywords
composition
substituted
etp69
unsubstituted
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20172824T
Other languages
English (en)
Spanish (es)
Inventor
Carl Cotman
Larry Overman
Shikha Snigdha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2944446T3 publication Critical patent/ES2944446T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Networks Using Active Elements (AREA)
ES20172824T 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva Active ES2944446T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172690P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
ES2944446T3 true ES2944446T3 (es) 2023-06-21

Family

ID=57504356

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20172824T Active ES2944446T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva
ES16808065T Active ES2807878T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16808065T Active ES2807878T3 (es) 2015-06-08 2016-06-03 Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Country Status (11)

Country Link
US (5) US10272093B2 (cg-RX-API-DMAC7.html)
EP (2) EP3733188B1 (cg-RX-API-DMAC7.html)
JP (1) JP6851081B2 (cg-RX-API-DMAC7.html)
KR (1) KR102776570B1 (cg-RX-API-DMAC7.html)
CN (1) CN107849061B (cg-RX-API-DMAC7.html)
AU (2) AU2016276172B2 (cg-RX-API-DMAC7.html)
CA (1) CA2988568A1 (cg-RX-API-DMAC7.html)
ES (2) ES2944446T3 (cg-RX-API-DMAC7.html)
IL (1) IL256055B (cg-RX-API-DMAC7.html)
MX (1) MX2017015909A (cg-RX-API-DMAC7.html)
WO (1) WO2016200690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988568A1 (en) * 2015-06-08 2016-12-15 The Regents Of The University Of California Use of h3k9me3 modulation for enhancing cognitive function
US20200147099A1 (en) * 2017-06-20 2020-05-14 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
CN108434454B (zh) * 2018-03-16 2019-10-11 大连医科大学 Adar1在缓解认知功能障碍方面的应用
JP7716987B2 (ja) * 2019-05-02 2025-08-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｔｅｒｔ活性化療法を伴う方法および組成物
US20240009203A1 (en) * 2020-08-03 2024-01-11 Cedars-Sinai Medical Center Compositions and methods for treating alzheimer's disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534255B1 (en) * 2003-01-24 2009-05-19 Photothera, Inc Low level light therapy for enhancement of neurologic function
US20060019227A1 (en) * 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
US8221804B2 (en) * 2005-02-03 2012-07-17 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2649576A1 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
JP2009084271A (ja) * 2007-09-07 2009-04-23 Toyama Univ 脳由来神経栄養因子の発現誘導剤および発現誘導方法
CN102271763A (zh) * 2008-12-03 2011-12-07 麻省理工学院 抑制hdac2以促进记忆
DK2542084T3 (en) * 2010-03-04 2018-03-26 Merck Sharp & Dohme CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND THEIR USE IN TREATMENT OF PSYCHOTIC DISORDERS
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료
CA2900335C (en) * 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
US20160058754A1 (en) * 2013-04-17 2016-03-03 H. Lundbeck A/S Nalmefene for Treatment of Patients with Anxiety Disorder
CA2930874A1 (en) * 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss
CA2988568A1 (en) * 2015-06-08 2016-12-15 The Regents Of The University Of California Use of h3k9me3 modulation for enhancing cognitive function

Also Published As

Publication number Publication date
AU2019246902B2 (en) 2021-08-19
CN107849061A (zh) 2018-03-27
KR20180014432A (ko) 2018-02-08
CN107849061B (zh) 2021-05-14
EP3733188B1 (en) 2023-01-25
WO2016200690A1 (en) 2016-12-15
US10849910B2 (en) 2020-12-01
JP6851081B2 (ja) 2021-03-31
ES2807878T3 (es) 2021-02-24
AU2019246902A1 (en) 2019-10-31
US20240374608A1 (en) 2024-11-14
US20230057592A1 (en) 2023-02-23
EP3733188A1 (en) 2020-11-04
IL256055A (en) 2018-01-31
US20180228808A1 (en) 2018-08-16
EP3303347B1 (en) 2020-05-06
AU2016276172B2 (en) 2019-07-11
US10272093B2 (en) 2019-04-30
US11311551B2 (en) 2022-04-26
EP3303347A4 (en) 2019-03-06
EP3303347A1 (en) 2018-04-11
AU2016276172A1 (en) 2018-01-04
KR102776570B1 (ko) 2025-03-04
CA2988568A1 (en) 2016-12-15
US20210106590A1 (en) 2021-04-15
US20190209577A1 (en) 2019-07-11
MX2017015909A (es) 2018-05-07
JP2018516940A (ja) 2018-06-28
IL256055B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
Song et al. Cardiolipin remodeling by ALCAT1 links mitochondrial dysfunction to Parkinson’s diseases
ES2944446T3 (es) Uso de la modulación de H3K9me3 para potenciar la función cognitiva
Večeřa et al. HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia‐like animals
Choi et al. Effect of exercise-induced neurogenesis on cognitive function deficit in a rat model of vascular dementia
Bickford et al. Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases
Michaëlsson et al. The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive‐like rats
Wang et al. Pulsatilla chinensis saponins ameliorated murine depression by inhibiting intestinal inflammation mediated IDO1 overexpression and rebalancing tryptophan metabolism
Shelton et al. The effects of a novel inhibitor of tumor necrosis factor (TNF) alpha on prepulse inhibition and microglial activation in two distinct rodent models of schizophrenia
Ma et al. A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia
Ji et al. Blockade of adenosine A2A receptors reverses early spatial memory defects in the APP/PS1 mouse model of Alzheimer’s disease by promoting synaptic plasticity of adult-born granule cells
Luo et al. Fluoxetine ameliorates cognitive impairments induced by chronic cerebral hypoperfusion via down-regulation of HCN2 surface expression in the hippocampal CA1 area in rats
Du et al. Naringin alleviates fluoride-induced neurological impairment: a focus on the regulation of energy metabolism mediated by mitochondrial permeability transition pore
Li et al. ISRIB facilitates post-spinal cord injury recovery through attenuation of neuronal apoptosis and modulation of neuroinflammation
Rao et al. dBcAMP rescues the neurons from degeneration in kainic acid-injured hippocampus, enhances neurogenesis, learning, and memory
HK40040355A (en) Use of h3k9me3 modulation for enhancing cognitive function
HK40040355B (en) Use of h3k9me3 modulation for enhancing cognitive function
Uehara et al. Apocynin-tandospirone derivatives demonstrate antioxidant properties in the animal model of schizophrenia
CN115429782B (zh) 乙酸盐在制备预防或治疗神经系统发育障碍药物中的应用
Vittalrao et al. Cognitive Enhancing Activities of Coenzyme Q10, Ramipril, and Vinpocetine Through Modulating Neuroinflammatory Response and Oxidative Damage Inflicted by Acute REM Sleep Deprivation in Rats
Mithaiwala The Role of Oxidative Kynurenine Metabolism in Mediating Hippocampal Cognitive Deficits in a Mouse Model of Chronic Inflammation
Zhao et al. Ganoderma lucidum spore powder modulates Bcl-2 and Bax expression in the hippocampus and cerebral cortex, and improves learning and memory in pentylenetetrazole-kindled rats**★
Alfei Palloni et al. Learning experience determines the fate of fear memories after post-training manipulations
Chen et al. Sodium fluoride-induced cognitive impairment by suppressing synaptic protein expression and nerve cell development